SCHEMBL1337230

SCHEMBL1337230

Cn1nc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C)cc1COC(=O)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ CNR1 P21554 14/20 0.34
▸ CNR2 P34972 12/20 0.34
▸ GABRA1 P14867 4/20 0.33
▸ GABRG2 P18507 2/20 0.33
▸ GABRB3 P28472 2/20 0.33
▸ GABRA5 P31644 2/20 0.33
▸ ADRA2C P18825 2/20 0.33
▸ SLC6A3 Q01959 2/20 0.33
▸ EGFR P00533 1/20 0.33
▸ ALOX5 P09917 1/20 0.33
▸ ADORA3 P0DMS8 1/20 0.33
▸ MAPK3 P27361 1/20 0.33
▸ OPRL1 P41146 1/20 0.33
▸ SLC18A2 Q05940 1/20 0.33
▸ MAPK14 Q16539 1/20 0.33
▸ TMEM97 Q5BJF2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339358 0.86 CNR1 (0.38) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL1337046 0.86 GABRG2 (0.42) CNR1CNR2GABRA1GABRG2GABRB3
SCHEMBL1338233 0.85 GABRA1 (0.37) CNR1CNR2GABRA1GABRG2GABRB3
SCHEMBL1336992 0.85 RAB9A (0.55) NPC1RAB9ATDP1L3MBTL1CNR1
SCHEMBL1339526 0.85 CNR1 (0.36) NPC1RAB9ATDP1L3MBTL1CNR1
SCHEMBL1338687 0.84 GABRA1 (0.39) CNR1CNR2GABRA1GABRG2GABRB3
SCHEMBL1338929 0.82 POLB (0.39) NPC1RAB9ATDP1L3MBTL1CNR1
SCHEMBL1339072 0.81 CNR1 (0.38) CNR1CNR2GABRA1ADRA2CSLC6A3
Hydrochloric Acid SCHEMBL1339640 0.80 ALPL (0.36) TDP1
SCHEMBL3260114 0.80 ALPL (0.36) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 NPC1 428/4885RAB9A 2067/4885TDP1 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback